Pharma ‘product-hopping’ bill gets nod from House panel
Legislation that would bar branded pharmaceutical companies from engaging in tactics to delay generic competition got the greenlight from a House panel.
The House Judiciary Committee by voice vote approved a...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch